BidaskClub lowered shares of Sanofi (NYSE:SNY) from a hold rating to a sell rating in a research report released on Monday, July 24th.
Several other equities research analysts have also weighed in on SNY. J P Morgan Chase & Co reissued a sell rating on shares of Sanofi in a report on Thursday, March 30th. Argus initiated coverage on Sanofi in a report on Thursday, April 6th. They issued a buy rating and a $50.00 price objective for the company. HSBC Holdings plc lowered Sanofi from a hold rating to a reduce rating in a report on Friday, April 7th. Zacks Investment Research raised Sanofi from a hold rating to a buy rating and set a $50.00 price objective for the company in a report on Tuesday, April 11th. Finally, TheStreet raised Sanofi from a c+ rating to a b- rating in a report on Monday, April 24th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $54.00.
Sanofi (SNY) traded up 0.23% during trading on Monday, reaching $48.19. 573,279 shares of the company’s stock were exchanged. Sanofi has a 12 month low of $36.81 and a 12 month high of $50.24. The firm’s 50-day moving average price is $47.84 and its 200-day moving average price is $46.41. The firm has a market cap of $121.03 billion, a price-to-earnings ratio of 11.43 and a beta of 0.88.
Sanofi (NYSE:SNY) last announced its quarterly earnings data on Monday, July 31st. The company reported $0.74 earnings per share for the quarter, hitting the consensus estimate of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The company had revenue of $8.66 billion during the quarter, compared to analyst estimates of $8.71 billion. The business’s revenue for the quarter was down 2.3% on a year-over-year basis. On average, equities research analysts anticipate that Sanofi will post $3.26 EPS for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of SNY. Harbour Capital Advisors LLC bought a new position in shares of Sanofi during the first quarter valued at approximately $113,000. Parallel Advisors LLC increased its position in shares of Sanofi by 42.5% in the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock valued at $139,000 after buying an additional 875 shares in the last quarter. YorkBridge Wealth Partners LLC increased its position in shares of Sanofi by 33.7% in the second quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock valued at $147,000 after buying an additional 776 shares in the last quarter. Eagle Ridge Investment Management acquired a new stake in shares of Sanofi during the second quarter worth about $160,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC increased its stake in shares of Sanofi by 6,188.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock worth $171,000 after buying an additional 3,713 shares during the period. Institutional investors and hedge funds own 9.90% of the company’s stock.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
What are top analysts saying about Sanofi? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi and related companies.